Pfizer EPS - Earnings per Share 1986-2025 | PFE

Pfizer annual and quarterly earnings per share history from 1986 to 2025. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Pfizer EPS for the quarter ending June 30, 2025 was $0.51, a 5000% increase year-over-year.
  • Pfizer EPS for the twelve months ending June 30, 2025 was $1.88, a 517.78% decline year-over-year.
  • Pfizer 2024 annual EPS was $1.41, a 281.08% increase from 2023.
  • Pfizer 2023 annual EPS was $0.37, a 93.24% decline from 2022.
  • Pfizer 2022 annual EPS was $5.47, a 42.08% increase from 2021.
Pfizer Annual EPS
2024 $1.41
2023 $0.37
2022 $5.47
2021 $3.85
2020 $1.63
2019 $2.82
2018 $1.87
2017 $3.52
2016 $1.17
2015 $1.11
2014 $1.42
2013 $3.19
2012 $1.94
2011 $1.27
2010 $1.02
2009 $1.23
2008 $1.20
2007 $1.17
2006 $2.66
2005 $1.09
2004 $1.49
2003 $0.54
2002 $1.46
2001 $1.22
2000 $0.59
1999 $0.82
1998 $0.49
1997 $0.57
1996 $0.50
1995 $0.42
1994 $0.35
1993 $0.17
1992 $0.21
1991 $0.18
1990 $0.20
1989 $0.17
1988 $0.20
1987 $0.18
1986 $0.17
1985 $0.15
Pfizer Quarterly EPS
2025-06-30 $0.51
2025-03-31 $0.52
2024-12-31 $0.07
2024-09-30 $0.78
2024-06-30 $0.01
2024-03-31 $0.55
2023-12-31 $-0.59
2023-09-30 $-0.42
2023-06-30 $0.41
2023-03-31 $0.97
2022-12-31 $0.86
2022-09-30 $1.51
2022-06-30 $1.73
2022-03-31 $1.37
2021-12-31 $0.59
2021-09-30 $1.42
2021-06-30 $0.98
2021-03-31 $0.86
2020-12-31 $0.15
2020-09-30 $0.26
2020-06-30 $0.62
2020-03-31 $0.60
2019-12-31 $-0.11
2019-09-30 $1.36
2019-06-30 $0.89
2019-03-31 $0.68
2018-12-31 $-0.06
2018-09-30 $0.69
2018-06-30 $0.65
2018-03-31 $0.59
2017-12-31 $2.03
2017-09-30 $0.47
2017-06-30 $0.51
2017-03-31 $0.51
2016-12-31 $0.13
2016-09-30 $0.22
2016-06-30 $0.33
2016-03-31 $0.49
2015-12-31 $-0.03
2015-09-30 $0.34
2015-06-30 $0.42
2015-03-31 $0.38
2014-12-31 $0.19
2014-09-30 $0.42
2014-06-30 $0.45
2014-03-31 $0.36
2013-12-31 $0.44
2013-09-30 $0.39
2013-06-30 $1.98
2013-03-31 $0.38
2012-12-31 $0.84
2012-09-30 $0.43
2012-06-30 $0.43
2012-03-31 $0.24
2011-12-31 $0.18
2011-09-30 $0.48
2011-06-30 $0.33
2011-03-31 $0.28
2010-12-31 $0.35
2010-09-30 $0.11
2010-06-30 $0.31
2010-03-31 $0.25
2009-12-31 $0.06
2009-09-30 $0.43
2009-06-30 $0.34
2009-03-31 $0.40
2008-12-31 $0.04
2008-09-30 $0.34
2008-06-30 $0.41
2008-03-31 $0.41
2007-12-31 $0.40
2007-09-30 $0.11
2007-06-30 $0.18
2007-03-31 $0.48
2006-12-31 $1.31
2006-09-30 $0.46
2006-06-30 $0.33
2006-03-31 $0.56
2005-12-31 $0.36
2005-09-30 $0.22
2005-06-30 $0.47
2005-03-31 $0.04
2004-12-31 $0.37
2004-09-30 $0.44
2004-06-30 $0.38
2004-03-31 $0.30
2003-12-31 $-0.03
2003-09-30 $0.29
2003-06-30 $-0.48
2003-03-31 $0.76
2002-12-31 $0.46
2002-09-30 $0.38
2002-06-30 $0.31
2002-03-31 $0.31
2001-12-31 $0.30
2001-09-30 $0.33
2001-06-30 $0.29
2001-03-31 $0.30
2000-12-31 $0.23
2000-09-30 $0.21
2000-06-30 $0.18
2000-03-31 $-0.03
1999-12-31 $0.25
1999-09-30 $0.36
1999-06-30 $0.18
1999-03-31 $0.21
1998-12-31 $0.18
1998-09-30 $0.37
1998-06-30 $0.17
1998-03-31 $0.18
1997-12-31 $0.14
1997-09-30 $0.15
1997-06-30 $0.12
1997-03-31 $0.15
1996-12-31 $0.13
1996-09-30 $0.13
1996-06-30 $0.10
1996-03-31 $0.14
1995-12-31 $0.11
1995-09-30 $0.11
1995-06-30 $0.08
1995-03-31 $0.11
1994-12-31 $0.09
1994-09-30 $0.09
1994-06-30 $0.07
1994-03-31 $0.10
1993-12-31 $0.08
1993-09-30 $-0.05
1993-06-30 $0.07
1993-03-31 $0.08
1992-12-31 $0.07
1992-09-30 $0.07
1992-06-30 $0.03
1992-03-31 $0.03
1991-12-31 $0.00
1991-09-30 $0.00
1991-06-30 $0.00
1991-03-31 $0.00
1990-12-31 $0.04
1990-09-30 $0.00
1990-06-30 $0.00
1990-03-31 $0.00
1989-12-31 $0.02
1989-09-30 $0.00
1989-06-30 $0.00
1989-03-31 $0.00
1988-12-31 $0.04
1988-09-30 $0.00
1988-06-30 $0.05
1988-03-31 $0.00
1987-12-31 $0.04
1987-09-30 $0.00
1987-06-30 $0.00
1987-03-31 $0.00
1986-12-31 $0.00
1985-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $201.199B $100.330B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12